Cap­si­da and Ab­b­Vie make $70M up­front deal for ge­net­ic med­i­cines in eye dis­eases

Ab­b­Vie is ex­pand­ing its part­ner­ship with gene ther­a­py de­vel­op­er Cap­si­da in a deal to de­vel­op ge­net­ic ther­a­pies for eye dis­eases.

The deal comes with a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER